Flamel Technologies (FLML): Sodium Oxybate Getting Back On Track - Needham

September 27, 2016 6:20 AM EDT
Get Alerts FLML Hot Sheet
Price: $10.39 --0%

Rating Summary:
    6 Buy, 0 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 24 | Down: 17 | New: 14
Trade FLML Now!
Join SI Premium – FREE

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

Leerink Partners analyst, Jason Gerberry reiterated his Outperform rating on shares of Flamel Technologies (NASDAQ: FLML) after the company highlighted that the pivotal Phase 3 study (REST-ON) for the company's once-nightly sodium oxybate (similar to JAZZ’s Xyrem) commenced after a several month delay.

At the event, mgmt emphasized 3 key features it believes will differentiate m-SXB:

1) once-nightly dosing vs. Xyrem's twice-nightly dosing.

2) tamper-resistant packaging - FLML plans to package m-SXB in child resistant packaging and emphasized QD dosing mitigates the issue of having an unattended dose on the pts nightstand

3) tolerability benefit - mgmt believes less water consumed with QD dosed product could cut down on the frequency of nocturnal enuresis (bed wetting).

Key upcoming events for FLML include: (1) possible update on Xyrem 2.0 by end-2016, per JAZZ; (2) Xyrem patent updates over the next 12 months.

No change to the price target of $16.

For an analyst ratings summary and ratings history on Flamel Technologies click here. For more ratings news on Flamel Technologies click here.

Shares of Flamel Technologies closed at $13.36 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Management Comments

Related Entities

Needham & Company

Add Your Comment